SARS-CoV-2 Spike (N501) Neutralizing Antibody (COV2110)

USA

-20°C

The product is specific for N501 site of wild-type RBD.For specific mutant protein, the product recognizes wild-type RBD, RBD single mutant (E484K), and RBD single mutant (K417N), but not recognizes RBD single mutant (N501Y) and RBD triple mutant (K417N, E484K and N501Y), as seen in Figure 2.

Recombinant SARS-CoV-2 RBD Protein

Affinity chromatography

SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2), also known as 2019-nCoV, is a positive-sense single-stranded RNA virus. It caused coronavirus disease in 2019 (COVID-19). SARS-CoV-2 contains glycosylated spike (S) protein, which is composed of S1 subunit and S2 subunit. The S1 contains a receptor-binding domain (RBD) that can bind to ACE2 receptor on target cells. Lineage B.1.351 (a.k.a. 20H/501Y.V2) is a variant of SARS-CoV-2. It has multiple mutations in the RBD, including K417N, E484K, N501Y. Lineage B.1.1.7 (a.k.a. 20I/501Y.V1) is also a variant of SARS-CoV-2 and has a mutation called N501Y in the RBD.SARS-CoV-2 Spike (N501) Neutralizing Antibody (COV2110) is produced from cell culture in vitro under conditions free from animal-derived components. The product is a humanized neutralizing antibody, recognizing N501 site of wild-type RBD. When N501 is mutated to N501Y, the mutant RBD, such as RBD (B.1.1.7) and RBD (B.1.351) as seen in Figure 1, can’t be recognized by the product.